Clinical trial
A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic…
NCT00117442 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00117442 |
|---|---|
| Title | A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood |
| Official title | An Open-Label, Randomised Study of Multi-Cycle, Dose Intensive Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Lung Cancer, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel, pegfilgrastim |
| Enrollment | 61 |
| Start date | Aug 1, 2002 |
| Primary completion | Aug 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Jul 7, 2005 |
| Last update posted | May 13, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: